NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 35)
Posted On: 12/03/2024 3:00:21 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼